https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14924 Wed 11 Apr 2018 10:46:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30512 Wed 02 Oct 2019 10:14:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32446 Thu 27 Jan 2022 15:57:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38163 Thu 24 Aug 2023 15:10:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20488 Sat 24 Mar 2018 07:59:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34250 75% cure rate following chemotherapy; there is an increasing population of survivors who live with chronic bone defects. Studies suggest that these defects are the result of reduced bone from increased marrow fat formation and increased bone resorption following chemotherapy. These changes probably result from altered expression/activation of regulatory molecules or pathways regulating skeletal cell formation and activity. Treatment with methotrexate, an antimetabolite commonly used in childhood oncology, has been shown to increase levels of proinflammatory/pro-osteoclastogenic cytokines (e.g., enhanced NF-κB activation), leading to increased osteoclast formation and bone resorption, as well as to attenuate Wnt signaling, leading to both decreased bone and increased marrow fat formation. In recent years, understanding the mechanisms of action and potential health benefits of selected nutraceuticals, including resveratrol, genistein, icariin, and inflammatory fatty acids, has led to preclinical studies that, in some cases, indicate efficacy in reducing chemotherapy-induced bone defects. We summarize the supporting evidence.]]> Fri 22 Feb 2019 16:56:01 AEDT ]]>